Kawasaki syndrome: Immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin

Clinical and Experimental Immunology, Supplement

Volumn 104, Issue SUPPL. 1, 1996, Pages 49-54

  Leung, D Y M ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Coronary artery; Intravenous immune globulin; Kawasaki syndrome; Superantigen; Toxins

Indexed keywords

BACTERIAL TOXIN; IMMUNOGLOBULIN; SUPERANTIGEN;

CHILD; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTITOXINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 0029920575     PISSN: 09642536     EISSN: None     Source Type: Journal    
DOI: 10.1111/cei.1996.104.s1.49     Document Type: Article

References (41)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lym-phoid involvement with specific desquamation of the fingers and toes in children. Aererugi 1967; 16:178-222.
2. Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Am J Dis Child 1976; 130:599-607.
3. Tizard EJ, Suzuki A, Levin M et al. Clinical aspects of 100 patients with Kawasaki disease. Arch Dis Child 1991; 66:185-8.
4. Suzuki A, Kamiya T, Kuwahara N et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986; 7:3-9.
5. Newburger JW, Takahashi M, Beiser AS et al. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med 1986; 315:341-7.
6. Furusho K, Kamiya T, Nakano H et al. High dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; ii: 1055-8.
7. Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633-9.
8. American Heart Association Committee on Rheumatic Fever. Diagnostic Guidelines for Kawasaki Disease. J Am Med Assoc 1990; 44:1218-9.
9. Yanagawa H, Nakamura Y, Yashiro M et al. A nationwide incidence survey of Kawasaki disease in 1985-1986 in Japan. J Infect Dis 1988; 158:1296-301.
10. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987; 75:387-94.
11. Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysms in Kawasaki disease: an angiograph study. J Pediatr 1987; 111:705-10.
12. Tanaka N, Naoe S, Masuda H et al. Pathological study of sequelae of Kawasaki disease (MCLS). With special reference to the heart and coronary arterial lesions. Acta Pathol Jpn 1986; 36:1513-27.
13. Terai M, Kohno Y, Namba M et al. Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol 1990; 21:231-4.
14. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70:427-51.
15. Sato N, Sagawa K, Kato H et al. Immunopathology of the skin lesion in Kawasaki Disease. In: Takahashi M, Tauber K eds. Proceedings of the Fourth International Symposium on Kawasaki Disease. Dallas: American Heart Association, 1993;247-52.
16. Leung DYM, Chu ET, Wood N et al. Immunoregulatory T cell abnormalities in mucotaneous lymph node syndrome. J Immunol 1983; 130:2002-4.
17. Leung D, Cotran R, Kurt-Jones E et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989; ii:1298-302.
18. Furukawa S, Matsubara T, Jujoh K et al. Peripheral blood monocyte/macrophage and serum tumor necrosis factor in Kawasaki disease. Clin Exp Immunol 1988; 48:247-51.
19. Ueno Y, Takano N, Kanegane H et al. The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illness. Clin Exp Immunol 1989; 76:337-42.
20. Lang BA, Silverman ED, Laxer RM et al. Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr 1989; 115:939-43.
21. Leung DYM, Geha RS, Newburger JW et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells suceptible to lysis by antibodies circulating during Kawasaki Syndrome. J Exp Med 1986; 164:1958-72.
22. Leung D, Collins T, Lapierre L et al. IgM antibodies in the acute phase of Kawasaki Syndrome lyse cultured vascular endothelial cells stimulated by γ-interferon. J Clin Invest 1986; 77:1428-35.
23. Leung DYM, Burns J, Newburger J et al. Reversal of immunoregulatory abnormalities in Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79:468-72.
24. Pober J, Gimbrone Jr M, Lapierre L et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986; 137: 1893-6.
25. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 1992; 10:561-91.
26. Leung DYM. Kawasaki disease. Curr Opin Rheumatol 1993; 5:41-50.
27. Kotzin BL, Leung DYM, Kappler J et al. Superantigens and human disease. Adv Immunol 1993; 54:99-146.
28. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immunol 1989; 57:291-6.
29. Herman A, Croteau G, Sekaly R-P et al. HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells. J Exp Med 1990; 172:709-17.
30. Abe J, Kotzin BL, Jujo K et al. Selective expansion of T cells expressing T cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc Natl Acad Sci (USA) 1992; 89:4066-70.
31. Curtis N, Zheng R, Lamb JR et al. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995; 72:308-11.
32. Abe J, Kotzin BL, Meissner C et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 1993; 177:791-6.
33. Leung DYM, Meissner HC, Fulton DR et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342:1385-8.
34. Rowley AH, Shulman ST. Current therapy for acute Kawasaki syndrome. J Pediatr 1991; 118:987-91.
35. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; ii:765-8.
36. Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989; 53:8170-9.
37. Amran D, Renz H, Lack G et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180-6.
38. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91:602-7.
39. Sundel RP, Burns JC, Baker A et al. Gamma globulin retreatment in Kawasaki disease. J Pediatr 1993; 123:657-9.
40. Meissner HC, Schlievert PM, Leung DYM. The mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis. Immunol Rev 1994; 139:109-23.
41. Vergeront JM, Stolz SJ, Crass BA et al. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for Toxic Shock Syndrome. J Infect Dis 1983; 148:692-8.